A Study in Adults to Learn About Inherited Alpha-1 Antitrypsin Deficiency (AATD) and AATD Related Liver Problems
Key facts
- Who runs it
- Takeda
- Where
- Charleston, Gainesville, and Nashville, United StatesSee the 3 sitesAlso in 5 other countries, 5 sites
- Trial code
- Status
- Recruiting
- People taking part
- 500 people, planned
- Started
- 25 Sept 2024
- Expected to end
- 31 Dec 2031
- Type of study
- Observational, 2 groups
- Record updated
- 24 July 2026
Who can take part
- Age
- 18 years and older
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 10 criteriaShow less
Who can take part
- Participants who meet all the following criteria will be included in the study
- Cohorts 1 and 2:
- Willing to provide written informed consent to participate in the study
- >=18 years of age at enrollment in this study
- Participants with documented diagnosis of AATD, meeting the following criteria:; Cohort 1 (AATD-Pi*ZZ genotype/phenotype); Pi*ZZ genotype as documented from rapid genetic assay, sequencing, or polymerase chain reaction (PCR), or Pi*ZZ phenotype as documented from iso-electric focusing (IEF) electrophoresis; Cohort 2 (AATD-Pi*SZ genotype/phenotype with liver disease manifestation); Pi*SZ genotype as documented from rapid genetic assay, sequencing, or PCR, or Pi*SZ phenotype as documented from IEF electrophoresis, and; Moderate-advanced or severe liver disease manifestation as defined by either liver biopsy or surrogate laboratory or imaging measures
Who cannot take part
- Participants with prior participation in an interventional clinical trial evaluating liver or lung disease, or who have received an investigational AATD-directed therapy under a compassionate use program, will be excluded if they do not present one of the following:; A minimum washout period of 6 months has elapsed since the last dose of the investigational product; A history of having received placebo in prior interventional trials (to be evaluated on a case-by-case basis)
- History of liver transplant
- No results for either biopsies, magnetic resonance elastography (MRE), FibroScan (vibration controlled transient elastography [VCTE]), or Aspartate aminotransferase to platelet ratio index (APRI) in the 24 months prior to the index/enrollment date and has none of these tests ordered during the index period (i.e., index date +90 days)
- Participants who meet any following criteria will be excluded from the study
- Documented AATD genotype/phenotype other than Pi*ZZ or Pi*SZ
Where in United States
Also in 5 other countries, 5 sites
- University of South CarolinaCharleston, United StatesContact: Charlie Strange (principal investigator)Taking people
- University of FloridaGainesville, United StatesContact: Virginia Clark (principal investigator)Taking people
- Vanderbilt University Medical CenterNashville, United StatesContact: Suzanne Sharpton (principal investigator)Taking people
About the trial
What the trial wants to find out
The liver produces a protein called alpha-1 antitrypsin (AAT). AAT is normally released into the bloodstream. In some people, the liver makes an abnormal version of AAT, called Z-AAT. Z-AAT builds up in liver cells and also leads to low blood levels of AAT (called Alpha-1 Antitrypsin Deficiency or AATD). Over time, this build up leads to different stages of liver problems, if not treated. This is called natural history of AATD.
Read full original descriptionShow less
The main aim of this study is to learn about liver problems caused by AATD in adults when not treated over 4 to 8 years. Other aims are to learn what can predict the AATD-liver condition starting and getting better or worse, describe how this condition is currently being diagnosed and watched in normal care, and describe how the AATD also affects an adult's lung function.
Data in this study will be collected to include medical history of a participant, including the date AATD was first identified and/or the date on which the first AATD-related liver or lung problems were diagnosed. At study start and then every year until study end, participants will be asked to complete questionnaires (called patient-reported outcomes or PROs).
The 2 groups in the trial
- Cohort 1: AATD-Pi*ZZ Genotype/Phenotype
Participants who have been diagnosed with Alpha-1 Antitrypsin Deficiency homozygous ZZ (AATD-Pi\*ZZ) genotype/phenotype with or without liver disease manifestations (fibrosis- F0-F4dc) will be enrolled and data will be prospectively collected per routine care throughout the follow-up period.
- Cohort 2: AATD-Pi*SZ Genotype/Phenotype
Participants who have been diagnosed with alpha-1 antitrypsin deficiency heterozygous SZ (AATD-Pi\*SZ) genotype/phenotype with moderate-advanced or severe liver disease (F2-F4dc) manifestations will be enrolled and data will be prospectively collected per routine care throughout the follow-up period.
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Prospective Observational Study on the Natural History of Alpha-1 Antitrypsin Deficiency and Associated Liver Disease
- Record updated
- 24 July 2026